These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Synthesis and characterization of mesoporous magnetic nanocomposites wrapped with chitosan gatekeepers for pH-sensitive controlled release of doxorubicin.
    Author: Wu J, Jiang W, Shen Y, Jiang W, Tian R.
    Journal: Mater Sci Eng C Mater Biol Appl; 2017 Jan 01; 70(Pt 1):132-140. PubMed ID: 27770872.
    Abstract:
    Multifunctional nanocarriers based on the Fe3O4 nanoparticles core and mesoporous silica shell (mSiO2) were synthesized for controlled drug release through magnetic targeting and pH-sensitive performances. The developed Fe3O4@mSiO2 nanocarriers exhibited a suitable size (63nm) and good magnetic responsibility, doxorubicin (DOX) could be successfully loaded into the mesoporous of Fe3O4@mSiO2 via electrostatic interaction, and the drug loading content and loading efficiency are 29.3% and 93.6%, respectively. The chitosan (CS) was employed to wrap the Fe3O4@mSiO2-DOX as the blocking agent to inhibit premature drug release, and the final CS/Fe3O4@mSiO2-DOX exhibited excellent pH-sensitivity, 86.1% DOX was released within 48h at pH4.0. Furthermore, all the release behaviors fit the Higuchi model very well and a purely diffusion-controlled process played a major role on DOX release from CS/Fe3O4@mSiO2-DOX. In addition, MTT assays in human liver hepatocellular carcinoma cells (HepG2) demonstrated that the CS/Fe3O4@mSiO2-DOX had high anti-tumor activity, while the Fe3O4@mSiO2 nanocarriers were practically non-toxic. Thus, our results revealed that the CS/Fe3O4@mSiO2-DOX could play an important role in the development of intracellular delivery nanodevices for cancer therapy.
    [Abstract] [Full Text] [Related] [New Search]